Addex Therapeutics Regained Global Rights to GABAB Assets
The company reacquired its portfolio from Indivior following a strategic rationalization of research and development.
Updated on Sept. 25, 2026 in Healthcare
Live Poll
Does the consolidation of pharmaceutical research companies benefit the development of new treatments?
Addex Therapeutics has regained full global ownership of its GABAB positive allosteric modulator assets from Indivior UK Limited. This change allows the Geneva-based company to independently pursue new therapeutic indications for its chronic cough program.
Why it matters
The agreement termination follows Indivior's internal decision to rationalize its research and development pipeline ahead of a planned merger with Supernus Pharmaceuticals, Inc. Addex now has the freedom to advance these programs or seek alternative partnerships.
Addex holds a 20% equity interest in Neurosterix US Holdings LLC. The company is now evaluating strategic options for its GABAB positive allosteric modulator program, which includes chronic cough treatment candidates.
The players
Addex Therapeutics
A biopharmaceutical company headquartered in Geneva, Switzerland, that focuses on the discovery and development of allosteric modulators.
Indivior UK Limited
A pharmaceutical company that recently engaged in a research and development rationalization ahead of a merger.
Supernus Pharmaceuticals, Inc.
A specialty pharmaceutical company that is planning a merger with Indivior.
Neurosterix US Holdings LLC
A specialized entity in which Addex Therapeutics maintains a 20% equity interest.
The details
The portfolio transition returns full control of development candidates to Addex, which previously operated under a research collaboration with Indivior. With the rights returned, the firm plans to move forward with its research programs independently or through new external collaborations.
Timeline
Addex announced the return of the GABAB rights on September 25, 2026.
Market Landscape
This asset return is a direct consequence of the organizational streamlining accompanying the merger of Indivior and Supernus Pharmaceuticals, Inc. It reflects broader industry shifts where companies divest non-core R&D programs to prioritize resources before major corporate consolidations.
Investors and stakeholders should note that Addex has shifted to an independent development model for its chronic cough program. The company is actively pursuing new partnerships, which may influence its long-term corporate valuation and product pipeline progress.
The takeaway
The return of these rights grants Addex greater autonomy to manage its specific therapeutic assets. Future progress will depend on the company's ability to successfully secure new partnerships or self-fund its development timeline.
Further reading
For more on industry developments, visit our Healthcare section.
More information
For more information on the company's research portfolio, visit the Addex Therapeutics corporate website.
Live Poll
Does the consolidation of pharmaceutical research companies benefit the development of new treatments?
